Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection

Antiviral Therapy

Volumn 20, Issue 3, 2015, Pages 281-287

  Lisboa Neto, Gaspar ^a   Noble, Caroline F ^a   Rebello Pinho, João R ^a,b   Malta, Fernanda M ^a   Gomes Gouvêa, Michele S ^a   Alvarado Mora, Mónica V ^a   Da Silva, Mariliza H ^c,d   Leite, Andrea G B ^e   Piccoli, Leonora Z ^e   Rodrigues, Flaviane K ^f   Carrilho, Flair J ^a   Mendes Correa, Maria C ^a,f  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c DST   (Brazil)

^d Clinica Municipal de Especialidades Médicas   (Brazil)

^e Centro Especializado em Saúde   (Brazil)

^f FACULDADE DE MEDICINA DO ABC   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; PROTEINASE INHIBITOR; VIRUS PROTEIN;

ADULT; AGE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS SUBTYPE 1A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RNA EXTRACTION; VIRUS GENE; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; BRAZIL; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; MUTATION; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BRAZIL; COINFECTION; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; PROTEASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84937553923     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2873     Document Type: Article

References (37)

1. Guirao AA, Yuste SR, Regueiro BJ. [Epidemiology and clinical manifestations of viral hepatitis]. Enferm Infecc Microbiol Clin 2006; 24:264-276. Spanish.
2. Lin L, Verslype C, van Pelt JF, van Ranst M, Fevery J. Viral interaction and clinical implications of coinfection of hepatitis C virus with other hepatitis viruses. Eur J Gastroenterol Hepatol 2006; 18:1311-1319.
3. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26:401-412.
4. Pereira LM, Martelli CM, Moreira RC, et al. Prevalence and risk factors of hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis 2013; 13:60.
5. Soriano V, Labarga P. Treatment of hepatitis C in patients infected with human immunodeficiency virus in the directacting antiviral era. Infect Dis Clin North Am 2012; 26:931-948.
6. Wegzyn CM, Wyles D. Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). Curr Opin Pharmacol 2012; 12:556-561.
7. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New directacting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012; 61 Suppl 1:i36-i46.
8. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56:S88-S100.
9. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012; 26:487-503.
10. Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis 2013; 207 Suppl 1:S33-S39.
11. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48:1769-1778.
12. Paolucci S, Fiorina L, Piralla A, et al. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J 2012; 9:245.
13. Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013; 87:1544-1553.
14. Barnard RJ, Howe JA, Ogert RA, et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two Phase 3 boceprevir clinical studies. Virology 2013; 444:329-336.
15. Peres-da-Silva A, de Almeida AJ, Lampe E. Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naive patients. Arch Virol 2010; 155:807-811.
16. Hoffmann L, Ramos JA, Souza EV, et al. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Virol J 2013; 10:57.
17. Zeminian LB, Padovani JL, Corvino SM, Silva GF, Pardini MI, Grotto RM. Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors. Mem Inst Oswaldo Cruz 2013; 108:13-17.
18. Nishiya AS, de Almeida-Neto C, Ferreira SC, et al. HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, Brazil. PLoS ONE 2014; 9:e86413.
19. Chevaliez S, Bouvier-Alias M, Rodriguez C, Soulier A, Poveda JD, Pawlotsky JM. The Cobas AmpliPrep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA. J Clin Microbiol 2013; 51:1078-1082.
20. Sandres-Sauné K, Deny P, Pasquier C, et al. Determining hepatitis C genotype by analyzing the sequence of the NS5b region. J Virol Methods 2003; 109:187-193.
21. HCV Phenotype Working Group, HCV Drug Development Advisory Group. Clinically relevant HCV drug resistance mutations figure and tables. Ann Forum Collab HIV Res 2012; 14:1-10.
22. Halfon P, Bourlière M, Khiri H, et al. Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy. AIDS 2008; 22:1694-1696.
23. Trimoulet P, Belzunce C, Faure M, et al. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-co-infected patients. HIV Med 2011; 12:506-509.
24. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009; 49:1069-1082.
25. Vicenti I, Rosi A, Saladini F, et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother 2012; 67:984-987.
26. Treviño A, de Mendoza C, Parra P, et al. Natural polymorphisms associated with resistance to new antivirals against hepatitis C virus (HCV) in newly diagnosed HIV/HCV-co-infected patients in Spain. Antivir Ther 2011; 16:413-416.
27. Morsica G, Bagaglio S, Uberti-Foppa C, Galli L, Lazzarin A. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-co-infected individuals treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 51:106-108.
28. Olysio (simeprevir). Prescribing information 2013. Janssen Therapeutics, Titusville, NJ, USA.
29. Oliveira SB, Merchán-Hamann E, Amorim LD. HIV/AIDS coinfection with the hepatitis B and C viruses in Brazil. Cad Saude Publica 2014; 30:433-438.
30. Mendes-Correa MC, Cavalheiro NP, Mello C, Barone AA, Gianini RJ. Genotypic distribution of hepatitis C among hepatitis C and HIV co-infected patients in Brazil. Int J STD AIDS 2008; 19:595-599.
31. Rallón NI, Pineda JA, Soriano V, et al. Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients co-infected with HCV subtypes 1a or 1b. J Acquir Immune Defic Syndr 2012; 60:117-123.
32. Campiotto S, Pinho JRR, Carrilho FJ, da Silva LC, Bernardini AP. Hepatitis C virus (HCV) genotypes distribution in different Brazilian regions. XIIth International Congress of Virology (Paris). 27 July-1 August 2002, Paris, France. Abstract V-1014.
33. Campiotto S, Pinho JR, Carrilho FJ, et al. Geographic distribution of hepatitis C virus genotypes in Brazil. Braz J Med Biol Res 2005; 38:41-49.
34. Nakano T, Lu L, Liu P, Pybus OG. Viral gene sequences reveal the variable history of hepatitis C virus infection among countries. J Infect Dis 2004; 190:1098-1108.
35. Lenz, O, Verbinnen, T, Lin TI, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54:1878-1887.
36. Victrelis (boceprevir). Prescribing information 2011. Merck & Co., Whitehouse Station, NJ, USA.
37. Kim AY, Lauer GM, Ouchi K, et al. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood 2005; 105:1170-1178.